Impact of a Digital Lifestyle Intervention on Diabetes Self-Management: A Pilot Study
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F22%3A10444912" target="_blank" >RIV/00216208:11110/22:10444912 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00216224:14110/22:00125808
Výsledek na webu
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=aM_D5kLnx8" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=aM_D5kLnx8</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3390/nu14091810" target="_blank" >10.3390/nu14091810</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Impact of a Digital Lifestyle Intervention on Diabetes Self-Management: A Pilot Study
Popis výsledku v původním jazyce
The aim of this study was to provide preliminary evidence on the impact of the digital health application Vitadio on improving glycemic control in patients with type 2 diabetes mellitus. This was a 3-month, prospective, multicenter, open-label trial with an intraindividual control group. Participants received a digital lifestyle intervention. HbA1c levels were observed at 3 time points: retrospectively, at 3 months before app use; at baseline, at the start of usage; and 3 months after the start of use. In addition, changes in other metabolic parameters (fasting glucose, body weight, and waist circumference), patient reported outcomes (quality of life, self-efficacy, and depression), and data generated within the app (frequency of use, steps, and photos of meals) were evaluated. Repeated measures analysis of variance with the Bonferroni correction was used to assess the overall difference in HbA1c values between the intervention and the intraindividual control group, with p < 0.05 considered significant. Participants (n = 42) were 57 +/- 7.4 years old, 55% male, and with a mean baseline HbA1c of 7.9 +/- 1.0%. An average HbA1c reduction of -0.9 +/- 1.1% (p < 0.001) was achieved. The digital health application was effective in significantly reducing body weight (-4.3 +/- 4.5 kg), body mass index (-1.4 +/- 1.5 kg/m(2)), waist circumference (-5.7 +/- 15 cm), and fasting glucose (-0.6 +/- 1.3 mmol/L). The digital therapy achieved a clinically meaningful and significant HbA1c reduction as well as a positive effect on metabolic parameters. These results provide preliminary evidence that Vitadio may be effective in supporting patient diabetes management by motivating patients to adopt healthier lifestyles and improving their self-management.
Název v anglickém jazyce
Impact of a Digital Lifestyle Intervention on Diabetes Self-Management: A Pilot Study
Popis výsledku anglicky
The aim of this study was to provide preliminary evidence on the impact of the digital health application Vitadio on improving glycemic control in patients with type 2 diabetes mellitus. This was a 3-month, prospective, multicenter, open-label trial with an intraindividual control group. Participants received a digital lifestyle intervention. HbA1c levels were observed at 3 time points: retrospectively, at 3 months before app use; at baseline, at the start of usage; and 3 months after the start of use. In addition, changes in other metabolic parameters (fasting glucose, body weight, and waist circumference), patient reported outcomes (quality of life, self-efficacy, and depression), and data generated within the app (frequency of use, steps, and photos of meals) were evaluated. Repeated measures analysis of variance with the Bonferroni correction was used to assess the overall difference in HbA1c values between the intervention and the intraindividual control group, with p < 0.05 considered significant. Participants (n = 42) were 57 +/- 7.4 years old, 55% male, and with a mean baseline HbA1c of 7.9 +/- 1.0%. An average HbA1c reduction of -0.9 +/- 1.1% (p < 0.001) was achieved. The digital health application was effective in significantly reducing body weight (-4.3 +/- 4.5 kg), body mass index (-1.4 +/- 1.5 kg/m(2)), waist circumference (-5.7 +/- 15 cm), and fasting glucose (-0.6 +/- 1.3 mmol/L). The digital therapy achieved a clinically meaningful and significant HbA1c reduction as well as a positive effect on metabolic parameters. These results provide preliminary evidence that Vitadio may be effective in supporting patient diabetes management by motivating patients to adopt healthier lifestyles and improving their self-management.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
30202 - Endocrinology and metabolism (including diabetes, hormones)
Návaznosti výsledku
Projekt
—
Návaznosti
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Ostatní
Rok uplatnění
2022
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Nutrients [online]
ISSN
2072-6643
e-ISSN
2072-6643
Svazek periodika
14
Číslo periodika v rámci svazku
9
Stát vydavatele periodika
CH - Švýcarská konfederace
Počet stran výsledku
17
Strana od-do
1810
Kód UT WoS článku
000794653000001
EID výsledku v databázi Scopus
2-s2.0-85128762813